Aveanna Healthcare (AVAH) is a pediatric private-duty nursing operator with smaller home-health and medical-solutions segments (≈$1.7B market cap, $3B EV). The Q1 2026 10-Q printed a clean discriminator against pure-play home-health peer EHAB that elevates the thesis from quarterly beat to share migration. The stock has rallied month-to-date — some of the move is in — but the cross-ticker read remains underweight.

What the filing says

Q1 Adjusted EBITDA was $84.4M (+25.3% YoY) on the seasonally weakest quarter — annualized run-rate $337M against FY2026 guidance midpoint $320M. The Home Health & Hospice segment grew episodes +23.1%, episodic admissions +18.7%, and episodic mix reached 80.9% (vs 77.3% Q1 2025). PDS revenue grew +16.4% but gross margin compressed -140bps to 27.9% as labor cost growth (+8.1%) outpaced revenue rate (+5.7%); spread held flat at $12.38/hr. Medical Solutions printed 44.7% gross margin — top of management's "normalized 43-45%" range — confirming Q4's 50% was a one-time reserve release. The June 2026 swap expiry was resolved on April 14 with a $520M rate cap at 4.00% (premium $4.6M); net annual cost increase ≈$10M, well below the $20M+ feared.

What the market thinks

Mean analyst target $9.70 (+25.6%); median $10; Stephens raised May 15 to $11. Options: P/C OI 0.23 (4.4x calls), inverted IV term structure (vol expected to rise into earnings), calls IV 9% above puts (bullish directional skew). Implied P(stock > $10 by September) ≈30-35% from call deltas. Forward P/E 10.6x, current EV/EBITDA 9.4x on guide vs sector median 10-12x.

Why the gap exists

Pure-play comp EHAB reported Q1 Medicare admissions -0.4%, completed episodes -5.3%, ADC -8.6%, and segment EBITDA -8.4%. Same sector, same MA dynamic, same quarter — AVAH is the right side, EHAB is the wrong side. PNTG's headline +75% Medicare admissions is M&A-driven (Amedisys/UNH divestiture transitions); organic same-store is +9.2%, half of AVAH's +18.7%. The sell-side covers AVAH and EHAB as a basket and misses the discriminator. HUM (doubling individual MA margin 2026, 3% sustainable target by 2028, more cuts coming in 2027 bid) and UNH (dropping 1.3M MA members 2026, Optum Health streamlined risk membership ≈15%) commentary confirms the MA-to-FFS migration AVAH is harvesting via its 80.9% episodic mix is multi-year structural, not transient. CEO's Q4 deflection on MA exposure is now empirically validated.

Risks

• PDS gross margin trajectory: Q1 -140bps to 27.9% (floor of target). Q2 print is diagnostic: recovery >28% = seasonal; persists <28% = structural labor squeeze (~-$30M EBITDA drag annualized).
• DOJ grand jury subpoena: $1.4M Q1 legal cost, recurring, no scope/timing disclosed. Material tail — enforcement action could re-rate stock -30%+.
• $880M cap rollover Feb 2027: Sequential to June 2026 event; at SOFR 4.3%, replacement could add another ≈$15M/yr drag.
• OBBBA HCBS cuts: Activate FY2028 (provider tax caps, payment caps). HCBS waiver % of PDS revenue undisclosed.
• Idio variance partial: Structural estimate ≈50-65% (below 75% target). Sector beta to home-health basket warrants hedge consideration at material size.

Catalysts

• June 28, 2026 — Family First close expected (≈$23M run-rate EBITDA, not in current guide)
• August 6, 2026 — Q2 earnings: guide raise probable; binary inflection
• Q3 2026 (~Nov) — $880M cap rollover plan disclosure window
• Feb 28, 2027 — $880M cap at 2.96% expires
• FY2028 — OBBBA worst provisions activate

What would change our mind

Q2 guide CUT (not raise) invalidates the EBITDA-gap thesis. Q2 PDS gross margin <26% confirms structural labor squeeze. EHAB Q2 stabilizes — peer divergence narrows, discriminator weakens. DOJ 8-K with material findings activates the tail. State Medicaid HCBS rate action announced ahead of FY2028. Family First termination or HSR delay.

Forward view

Probability-weighted 12-month range: $5-12, EV ≈$9.65. Bull case ($12.13, 11x EV/EBITDA on $360M post-Family First) at ≈35%; base ($9.80, 10x on $345M) at 30%; sideways ($8.04, 9x on $340M) at 20%; bear states 14%; catastrophic 1%. 4:1 bull/bear asymmetry. Market consensus is approximately calibrated to the EV midpoint; edge concentrates in probability mass on the bull case driven by the cross-ticker peer divergence and run-rate beat math not yet reflected in mean target $9.70.

Evidence